Protara Therapeutics Q3 net loss widens

Protara Therapeutics

10/11/2025 13:11

Overview

Protara reports Q3 net loss of $13.3 mln, increased from $11.2 mln in 2024

Company anticipates key clinical milestones in late 2025 and early 2026

Outlook

Protara expects interim results from NMIBC trial in 1Q 2026

Company plans to initiate dosing in THRIVE-3 trial by year-end 2025

Protara expects cash reserves of $134 mln to support operations into mid-2027

Result Drivers

CLINICAL TRIAL PROGRESS - Protara continues to advance its clinical programs with significant milestones expected in late 2025 and early 2026, including interim analyses for TARA-002 in NMIBC and LMs

THRIVE-3 TRIAL - Dosing in the THRIVE-3 trial for IV Choline Chloride is expected to begin by year-end 2025, addressing administrative and funding challenges

CASH POSITION - Protara's cash reserves of $134 mln are expected to support operations into mid-2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.31
Q3 Net Income
-$13.26 mln
Q3 Income from Operations
-$14.76 mln
Q3 Operating Expenses
$14.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Protara Therapeutics Inc is $24.50, about 82.5% above its November 7 closing price of $4.29

Press Release: ID:nGNX5GphFj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)